Literature DB >> 31295426

Non-traditional Antibacterial Therapeutic Options and Challenges.

Ursula Theuretzbacher1, Laura J V Piddock2.   

Abstract

The global challenges presented by drug-resistant bacterial infections have stimulated much activity in finding new treatments. This review summarizes the progress and setbacks of non-traditional approaches intent on circumventing bacterial drug resistance. These approaches include targeting virulence via toxin production and virulence factor secretion, impeding bacterial adhesion to host cells and biofilm formation, interrupting or inhibiting bacterial communication, and downregulating virulence. Other strategies include immune evasion, microbiome-modifying therapies, and the employment of phages as treatments or carriers. Finally, the prospects of nanoparticles, immunotherapy, antisense RNA, and drug-resistance-modulation approaches are discussed. The development of non-traditional treatments suffers similar challenges faced by developers of conventional antibiotics; however, most of these new strategies have additional and considerable hurdles before it can be shown that they are safe and efficacious for patient use. For the foreseeable future, it is likely that most of these treatments, if approved, will be used in combination with antibiotics.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anti-virulence; antisense RNA; immunotherapy; microbiome; nanoparticles; non-traditional antimicrobials; phage; quorum-sensing

Mesh:

Year:  2019        PMID: 31295426     DOI: 10.1016/j.chom.2019.06.004

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  44 in total

Review 1.  Critical analysis of antibacterial agents in clinical development.

Authors:  Ursula Theuretzbacher; Karen Bush; Stephan Harbarth; Mical Paul; John H Rex; Evelina Tacconelli; Guy E Thwaites
Journal:  Nat Rev Microbiol       Date:  2020-03-09       Impact factor: 60.633

2.  A war of attrition against antibiotic resistance: Current strategies try to keep antibiotic resistance at bay and further encourage research to produce genuinely novel antibacterials.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2020-05-24       Impact factor: 8.807

Review 3.  Targeting evolution to inhibit antibiotic resistance.

Authors:  Houra Merrikh; Rahul M Kohli
Journal:  FEBS J       Date:  2020-06-08       Impact factor: 5.542

4.  Structure, Assembly, and Function of Tripartite Efflux and Type 1 Secretion Systems in Gram-Negative Bacteria.

Authors:  Ilyas Alav; Jessica Kobylka; Miriam S Kuth; Klaas M Pos; Martin Picard; Jessica M A Blair; Vassiliy N Bavro
Journal:  Chem Rev       Date:  2021-04-28       Impact factor: 60.622

5.  Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis.

Authors:  Vincent Trebosc; Valentina Lucchini; Mohit Narwal; Basil Wicki; Sarah Gartenmann; Birgit Schellhorn; Julian Schill; Marilyne Bourotte; Daniel Frey; Jürgen Grünberg; Andrej Trauner; Livia Ferrari; Antonio Felici; Olivia L Champion; Marc Gitzinger; Sergio Lociuro; Richard A Kammerer; Christian Kemmer; Michel Pieren
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

Review 6.  Antibiofilm activity of host defence peptides: complexity provides opportunities.

Authors:  Morgan A Alford; Evan F Haney; Robert E W Hancock
Journal:  Nat Rev Microbiol       Date:  2021-06-28       Impact factor: 60.633

7.  Efficacy of Nanoencapsulated Daptomycin in an Experimental Methicillin-Resistant Staphylococcus aureus Bone and Joint Infection Model.

Authors:  Cedric Jacqueline; Jocelyne Caillon; Olivier Meyer; Eric Dailly; Carl Simonsson; Vincent Lenaerts; Karim Asehnoune; Amokrane Reghal; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

Review 8.  Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections.

Authors:  João Victor de Oliveira Santos; Ana Lúcia Figueiredo Porto; Isabella Macário Ferro Cavalcanti
Journal:  Antibiotics (Basel)       Date:  2021-05-02

9.  Biochemical and structural studies of target lectin SapL1 from the emerging opportunistic microfungus Scedosporium apiospermum.

Authors:  Dania Martínez-Alarcón; Viviane Balloy; Jean-Philippe Bouchara; Roland J Pieters; Annabelle Varrot
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

Review 10.  Supramolecular Peptide Assemblies as Antimicrobial Scaffolds.

Authors:  Andrew W Simonson; Matthew R Aronson; Scott H Medina
Journal:  Molecules       Date:  2020-06-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.